title: [A cost-effectiveness analysis on universal infant rotavirus vaccination strategy in China].
abstract: OBJECTIVE
  To evaluate the cost-effectiveness of current universal infant rotavirus vaccination strategy, in China.
  
  
  METHODS
  Through constructing decision tree-Markov model, we simulated rotavirus diarrhea associated cost and health outcome on those newborns in 2012 regarding different vaccination programs as: group with no vaccination, Rotavirus vaccination group and Rotateq vaccination group, respectively. We determined the optimal program, based on the comparison between incremental cost-effectiveness ratio (ICER) and China' s 2012 per capital gross domestic product (GDP).
  
  
  RESULTS
  Compared with non-vaccination group, the Rotavirus vaccination and Rotateq vaccination groups had to pay 3 760 Yuan and 7 578 Yuan (both less than 2012 GDP per capital) to avert one disability adjusted life years (DALY) loss, respectively. RESULTS from sensitivity analysis indicated that both results were robust. Compared with Rotavirus vaccination program, the Rotateq vaccination program had to pay extra 81 068 Yuan (between 1 and 3 times GDP per capital) to avert one DALY loss. Data from the sensitivity analysis indicated that the result was not robust.
  
  
  CONCLUSIONS
  From the perspective of health economics, both two-dose Rotarix vaccine and three-dose' s Rotateq vaccine programs were highly cost-effective, when compared to the non-vaccination program. It was appropriate to integrate rotavirus vaccine into the routine immunization program. Considering the large amount of extra cost that had to spend on Rotateq vaccination program, results from the sensitivity analysis showed that it was not robust. Rotateq vaccine required one more dose than the Rotarix vaccine, to be effective. However, it appeared more difficult to practice, suggesting that it was better to choose the Rotarix vaccine, at current stage.
authors.affiliation: Department of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an 710061, China.
authors.forename: S L
authors.initials: SL
authors.lastname: Sun
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Gao
authors.forename: J
authors.initials: J
authors.lastname: Yin
authors.forename: G H
authors.initials: GH
authors.lastname: Zhuang
mesh_terms: D002681:China; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D003967:Diarrhea / Q000191:economics / Q000821:virology; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007231:Infant, Newborn; D008390:Markov Chains; D019057:Quality-Adjusted Life Years; D012400:Rotavirus Infections / Q000191:economics / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000191:economics*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000191:economics
chemical_list: C492457:RIX4414 vaccine; C492535:RotaTeq; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated